CRISPR THERAPEUTICS AG (CRSP) Free cash flow 2016–2025
CRISPR THERAPEUTICS AG (CRSP) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$345.9MFY2025 · since FY2016: -$55.9M → -$345.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$345.9M | -139.1% |
| FY2024 | -$144.7M | +46.4% |
| FY2023 | -$269.8M | +49.4% |
| FY2022 | -$532.9M | -216.5% |
| FY2021 | $457.3M | +278.1% |
| FY2020 | -$256.7M | -613.5% |
| FY2019 | $50.0M | +150.5% |
| FY2018 | -$99.0M | -27.1% |
| FY2017 | -$77.9M | -39.4% |
| FY2016 | -$55.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CRSP financial trends
CRSP RevenueCRSP Net incomeCRSP Net marginCRSP Gross profitCRSP Gross marginCRSP Operating incomeCRSP Operating marginCRSP Operating cash flowCRSP Capital expendituresCRSP Return on equityCRSP Stock buybacksCRSP Dividends paidCRSP Total assetsCRSP Total liabilitiesCRSP Shareholders’ equityCRSP overview →